Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FRK | P42685 | 1/20 | 0.42 |
| ▸ | SIK1 | P57059 | 1/20 | 0.42 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | SRMS | Q9H3Y6 | 1/20 | 0.42 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299594 | 0.94 | CYP2C9 (0.88) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL291570 | 0.93 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL294562 | 0.91 | CYP2C9 (0.84) | CYP2C9CYP3A4CYP2C19BRAF | |
| SCHEMBL299314 | 0.91 | CYP2C9 (0.82) | CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL298852 | 0.89 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2C19PIK3CACYP2D6 | |
| SCHEMBL295492 | 0.89 | CYP2C9 (0.84) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL297405 | 0.89 | CYP2C9 (0.79) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL298244 | 0.88 | CYP3A4 (0.84) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL297967 | 0.87 | CYP2C9 (0.77) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL299237 | 0.87 | CYP2C9 (0.76) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | claimed |
| EP-2427462-A1 | PYRROLO [2, 3. B]PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | claimed |
| WO-2010129567-A1 | PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | claimed |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427462-A1 | PYRROLO [2, 3. B]PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129567-A1 | PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2C9 2176/4885CYP3A4 3611/4885CYP2C19 2730/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | CYP2C9 2237/4885CYP3A4 2892/4885CYP2C19 2678/4885 |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | CYP2C9 2237/4885CYP3A4 2892/4885CYP2C19 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.